Sterne Agee Still Has Confidence In Actavis plc

Loading...
Loading...
In a report published Wednesday, Sterne Agee analyst Shibani Malhotra reiterated a Buy rating and $272.00 price target on
Actavis plcACT
. In the report, Sterne Agee noted, “Although Actavis failed to garner support at today's FDA AdCom for the product, we do not see this as being very meaningful to longer-term growth and earnings potential. Per our estimates, removing this product from our revenue estimates decreases our 2018E EPS by less than 1% (see Exhibit 1 below). We believe that the company still has many levers to drive meaningful EPS growth and easily reach its 2017 EPS target of ~$20.” Actavis closed on Tuesday at $232.61.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsShibani MalhotraSterne Agee
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...